Seeing Is Believing
Currently out of the existing stock ratings of Steve Byrne, 34 are a SELL (20.12%), 79 are a BUY (46.75%), 56 are a HOLD (33.14%).
Analyst Steve Byrne, currently employed at BAML, carries an average stock price target met ratio of 66.41% that have a potential upside of 20.36% achieved within 231 days.
Steve Byrne’s has documented 504 price targets and ratings displayed on 32 stocks. The coverage is on Basic Materials, Consumer Defensive, Healthcare sectors.
Most recent stock forecast was given on CE, Celanese at 12-Aug-2024.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for GPRE (GREEN PLAINS RENEWABLE ENERGY) at 10/24/2022. The price target of $35 was fulfilled within 17 days with a profit of $7.74 (28.39%) receiving and performance score of 16.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
170
$79.75 (88.37%)
190
3 days ago
5/8 (62.5%)
$82 (93.18%)
87
Hold
78
$-12.25 (-13.57%)
250
12 days ago
3/4 (75%)
$-4.78 (-5.77%)
46
Hold
80
$-10.25 (-11.36%)
140
15 days ago
5/10 (50%)
$0.63 (0.79%)
30
Sell
90
$-0.25 (-0.28%)
95
23 days ago
4/9 (44.44%)
$8.17 (9.98%)
14
Buy
111
$20.75 (22.99%)
157
25 days ago
20/30 (66.67%)
$31.47 (39.57%)
352
Which stock is Steve Byrne is most bullish on?
Which stock is Steve Byrne is most reserved on?
What Year was the first public recommendation made by Steve Byrne?